Industry Blog

Patients miss out on treatment as drugs sold abroad.

Drug wholesalers selling on supplies abroad to increase profit means UK patients are lost out on necessary medicines.

The Royal Pharmaceutical Society says “urgent action is needed and that patients’ lives are being put at risk”.

It says UK pharmacies looking to raise shortages of over 40 familiar drugs used to care for conditions like cancer, high blood pressure and epilepsy.

The problem seems to be caused by the weak pound which makes it more profitable to sell medicines abroad.

The Royal Pharmaceutical Society of Great Britain says drugs manufacturers and wholesalers are restraining the materials they send individual pharmacies.

This means that when pharmacists go over their quota, they are having to spend hours negotiating for further supplies, which occasionally takes weeks to get there.

At Mount Elgon pharmacy in south London, pharmacist Raj Patel has had to deal with dozens of concerned patients. “It feels as if we’re constantly fighting a losing battle,” he said.

Minster surges on agreed bid

The New Year started extremely well for Mister Pharmaceuticals when agreeing to a take over by Proximagen for £4.3 Million. 

Shares rose 1.68p to 5.8p in the developer of drugs for neurological and psychiatric disorders after proximagen said that it would pay 6p a share for the group.

Proximagen were down 1p to 109p and raised £50 million last year to follow its strategy of buying smart drug programmes.

John Russell, Minster’s chairman and chief executive, said” I thought the offer provided a more certain investment outcome for shareholders given that the group’s prospects, without the funding it needs to progress its business plan, were very uncertain”.

Dr Kenneth Mulvany, the chief executive of Proximagen, said “I was particularly interested in Minster’s tonabersat compound, bought from GlaxoSmithKline, which he thinks has the potential for the treatment of epilepsy”.

New technology to spot fakes

Space-age technology is being used in a new, quick way of detecting fake pharmaceuticals, a university has said.

The Spectral ID project helps identify counterfeit drugs where differences cannot be seen by the untrained eye.

Developed from a spectrograph originally designed for astronomical research, trials have so far had a 100% success rate and the scientists behind it have been shortlisted for an award.

The project, which began in 2005, has been undertaken by Professor George Fraser and Professor Martin Gill, from the University of Leicester.

They found the need for a system that could quickly identify a counterfeit drug product in the field, rather than existing solutions involving costly laboratory testing.

Prof Fraser, director of the university’s Space Research Centre, said: “Pharmaceutical manufacturers do not have a simple to use, speedy, non-destructible method of detecting counterfeits and we have the potential to offer just that.

“Feedback results from the use of our device are obtained within seconds.”

The technique relies on detecting the differences between the characteristics of light reflected from printed packaging.

Dr Nigel Bannister, also from the Space Research Centre, was responsible for the Faulkes Telescope spectrometer, used to make the original tests on counterfeit goods.

The space-age technology was developed with help from University of Leicester spin-out company Perpetuity Research and Consultancy International (PRCI) for use in removing counterfeit drugs from the market.

 

www.google.com

Pharmaceutical giants in Stevenage gives antivirals to all staff.

PHARMACEUTICAL giants GlaxoSmithKline (GSK), which has a base in Stevenage, has issued all its UK employees and their families with the antiviral drug to swine flu “in case of need”.

Tamiflu has been given to workers as a precautionary measure to fight the H1N1 virus.

A spokesman for the company said: “GSK has invoked its own internal pandemic preparedness plan, to ensure continuity of supply of all its critical medicines and vaccines.”

At the end of May, GSK started production of a swine flu vaccine and has so far received orders for 195 million doses.

First supplies will be available from September.

It also expects to increase annual production of Relenza - which can both treat and help prevent flu - from 60 million to 190 million by the end of the year.

www.thecomet.net

Tag Cloud